Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial

Ranjana H. Advani, MD, Stephen M. Ansell, M.D., Ph.D., Mary J Lechowicz, MD, Anne W Beaven, MD, Fausto R. Loberiza, Jr., MD, MS, Kenneth R Carson, MD, Andrew M Evens, DO, MSc, Francine M. Foss, MD, Steven M. Horwitz, MD, Barbara Pro, MD, Lauren Pinter-Brown, MD, Sonali M. Smith, MD, Andrei R. Shustov, MD, Kerry J. Savage, MD, MSc, Julie M Vose, MD, MBA

Blood (2013) 122 (21): 3044.

https://doi.org/10.1182/blood.V122.21.3044.3044

Published: 2013

Journal Articles

Disparity In Clinical Outcomes Of Elderly Patients With Non-Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation According To Area Of Residence

Andrew C. Cannon, B.S., James Olen Armitage, MD, Philip Bierman, MD, R. Gregory Bociek, MD, Julie M. Vose, MD, Fausto R. Loberiza, Jr., MD, MS

Blood (2013) 122 (21): 1744.

https://doi.org/10.1182/blood.V122.21.1744.1744

Published: 2013

Journal Articles

Lack Of Clinical Benefit For Routine Surveillance Imaging For Diffuse Large B-Cell Lymphoma In First Complete Remission

Julie M Vose, MD, MBA, Ravi Pingali, MD, Nina Wagner-Johnson, MD, Fausto R. Loberiza, Jr., MD, MS, Timothy S. Fenske, MD, Sarah Jewell, Martin Bast, BS, Nancy L. Bartlett, MD, James O. Armitage, MD

Blood (2013) 122 (21): 4303.

https://doi.org/10.1182/blood.V122.21.4303.4303

Published: 2013

Journal Articles

Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR)

Navneet S. Majhail, MD, MS, Tammy Payton, BS, Lih-Wen Mau, PhD, MPH, Jennifer Le Rademacher, PhD, Pintip Chitphakdithai, PhD, Michael Eckrich, MD, Steven Joffe, MD, MPH, Stephanie J. Lee, MD, MPH, Charles F. LeMaistre, MD, Fausto R. Loberiza, Jr., MD, MS, Brent R. Logan, PhD, Elizabeth A Murphy, RN, ScD, Susan K. Parsons, MD, MRP, Ramona Repaczki-Jones, J. Douglas Rizzo, MD, Pam Robinett, Ellen Denzen, MS

Blood (2013) 122 (21): 1687.

https://doi.org/10.1182/blood.V122.21.1687.1687

Published: 2013

Journal Articles

Time To Insurance Approval Of Hematopoietic Stem Cell Transplantation (HSCT) Between Private and Public Payers Is Not Associated With Survival

Fausto R Loberiza, Jr., MD, MS, Derek P Bumgardner, B.S., Veenu Minhas, Ph.D., Andrew C Cannon, B.S., Stephanie J. Lee, MD, MPH

Blood (2013) 122 (21): 723.

https://doi.org/10.1182/blood.V122.21.723.723

Published: 2013

Journal Articles

Phase I/II Trial of Ofatumumab/Lenalidamide for Patients with Relasped/Refractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma

Julie M Vose, MD, MBA, Fausto R. Loberiza, Jr., MD, MS, R. Gregory Bociek, MD, Philip Bierman, MD, James O. Armitage, MD

Blood (2012) 120 (21): 3692.

https://doi.org/10.1182/blood.V120.21.3692.3692

Published: 2012

Journal Articles

Lymphoma with Features Intermediate Between DLBCL and Burkitt Lymphoma: Better Outcome with Intensive Chemotherapy Regimens

David G Crockett, MD, Anamarija M. Perry, MD, James O. Armitage, MD, Dennis D Weisenburger, MD, Martin Bast, BS, Fausto R. Loberiza, Jr., MD, MS

Blood (2011) 118 (21): 2710.

https://doi.org/10.1182/blood.V118.21.2710.2710

Published: 2011

Journal Articles

A Retrospective Analysis Comparing BEAM Versus Melphalan Prior to First Autologous Peripheral Blood Hematopoietic Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Patients

Edward Anthony Faber, Jr., DO, MS, Fausto R. Loberiza, Jr., MD, MS, Mojtaba Akhtari, Philip Bierman, MD, R. Gregory Bociek, MD, Lori Maness, M.D., Julie M Vose, MD

Blood (2011) 118 (21): 2040.

https://doi.org/10.1182/blood.V118.21.2040.2040

Published: 2011

Journal Articles

Trend Analysis of 5-Year All-Cause Mortality After Autologous Stem Cell Transplantation in Patients with Lymphoma and Multiple Myeloma

Mojtaba Akhtari, MD, James O. Armitage, Philip Bierman, MD, R. Gregory Bociek, MD, Edward Anthony Faber, Jr., DO, MS, Lori Maness, M.D., Julie M Vose, MD, Fausto R. Loberiza, Jr., MD, MS

Blood (2011) 118 (21): 842.

https://doi.org/10.1182/blood.V118.21.842.842

Published: 2011

Journal Articles

What Predicts Agreement about Prognosis Between Patients and Physicians?

Amy Sullivan, ScD, Stewart Alexander, PhD, Anthony Back, MD, Maureen Wilson-Genderson, PhD, Fausto R. Loberiza, Jr., MD, MS, James Tulsky, MD, Susan Block, MD, Stephanie J. Lee, MD, MPH

Blood (2011) 118 (21): 1021.

https://doi.org/10.1182/blood.V118.21.1021.1021

Published: 2011

Journal Articles

Rituximab Added to Aggressive Chemotherapy Improves the Outcome of Patients with Follicular Lymphoma, Grade 3 and Results In Survival Comparable to Diffuse Large B-Cell Lymphoma.

Philip J. Bierman, MD, Julie M. Vose, MD, R. Gregory Bociek, MD, Fausto R. Loberiza, Jr., MD, MS, Martin Bast, BS, James O. Armitage, MD

Blood (2010) 116 (21): 2810.

https://doi.org/10.1182/blood.V116.21.2810.2810

Published: 2010

Journal Articles

High-Dose Therapy (HDT) with Hematopoietic Stem Cell Transplantation (HSCT) Is Effective Therapy for Patients with Non-Hodgkin Lymphoma (NHL) and Central Nervous System (CNS) Involvement

R. Gregory Bociek, MD, Peerapon Wong, MD, Fausto R. Loberiza, Jr., MD, MS, Philip Bierman, MD, Julie M. Vose, Nicole Shonka, MD, James O. Armitage, MD

Blood (2010) 116 (21): 1358.

https://doi.org/10.1182/blood.V116.21.1358.1358

Published: 2010

Journal Articles

Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Basem M. William, MD, MRCP, Maribeth Hohenstein, RN, BSN, OCN, Fausto R. Loberiza, Jr., MD, MS, Gabriel C. Caponetti, MD, R. Gregory Bociek, MD, Philip Bierman, MD, James O. Armitage, MD, Wing-Chung Chan, MD, Julie M. Vose, MD

Blood (2010) 116 (21): 288.

https://doi.org/10.1182/blood.V116.21.288.288

Published: 2010

Journal Articles

Survival Disparities in Patients with Lymphoma According to Place of Residence and Treatment Provider: A Population-Based Study

Fausto R Loberiza, Jr., MD, MS, Anthony J Cannon, Dennis D Weisenburger, MD, Julie M. Vose, MD, Matt J. Moehr, MS, Martin A. Bast, Philip Bierman, MD, R. Gregory Bociek, MD, James Olen Armitage, MD

Blood (2008) 112 (11): 874.

https://doi.org/10.1182/blood.V112.11.874.874

Published: 2008

Journal Articles

Prevalence of Microbially Contaminated Hematopoietic Stem Cell Products.

Richard E. Champlin, MD, Fausto R. Loberiza, Jr., MD, MS, Mary Eapen, MD, MS, J. Douglas Rizzo, MD, Christopher N. Bredeson, MD, MSc, John E. Wagner, MD, Mary M. Horowitz, MD, MS, on behalf of the Histocompatibility Alternative Stem Cell Sources Working Committee of the Center for International Blood Marrow Transplant Research (CIBMTR)

Blood (2004) 104 (11): 2228.

https://doi.org/10.1182/blood.V104.11.2228.2228

Published: 2004

NARROW

A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial

Disparity In Clinical Outcomes Of Elderly Patients With Non-Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation According To Area Of Residence

Lack Of Clinical Benefit For Routine Surveillance Imaging For Diffuse Large B-Cell Lymphoma In First Complete Remission

Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR)

Time To Insurance Approval Of Hematopoietic Stem Cell Transplantation (HSCT) Between Private and Public Payers Is Not Associated With Survival

Phase I/II Trial of Ofatumumab/Lenalidamide for Patients with Relasped/Refractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma

Lymphoma with Features Intermediate Between DLBCL and Burkitt Lymphoma: Better Outcome with Intensive Chemotherapy Regimens

A Retrospective Analysis Comparing BEAM Versus Melphalan Prior to First Autologous Peripheral Blood Hematopoietic Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Patients

Trend Analysis of 5-Year All-Cause Mortality After Autologous Stem Cell Transplantation in Patients with Lymphoma and Multiple Myeloma

What Predicts Agreement about Prognosis Between Patients and Physicians?

Rituximab Added to Aggressive Chemotherapy Improves the Outcome of Patients with Follicular Lymphoma, Grade 3 and Results In Survival Comparable to Diffuse Large B-Cell Lymphoma.

High-Dose Therapy (HDT) with Hematopoietic Stem Cell Transplantation (HSCT) Is Effective Therapy for Patients with Non-Hodgkin Lymphoma (NHL) and Central Nervous System (CNS) Involvement

Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Survival Disparities in Patients with Lymphoma According to Place of Residence and Treatment Provider: A Population-Based Study

Prevalence of Microbially Contaminated Hematopoietic Stem Cell Products.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only